07:00 , Sep 21, 2015 |  BC Week In Review  |  Company News

Amgen, NantWorks deal

Amgen granted NantWorks’ NantPharma LLC subsidiary exclusive, worldwide rights to develop and commercialize AMG 337, excluding Japan, Russia and certain countries in central Asia. AMG 337, a small molecule inhibitor of c-Met receptor...
00:57 , Sep 15, 2015 |  BC Extra  |  Company News

NantPharma licenses Amgen's AMG 337

Amgen Inc. (NASDAQ:AMGN) granted NantPharma LLC exclusive, worldwide rights to develop and commercialize AMG 337, excluding Japan, Russia and certain countries in central Asia. NantPharma is one of several subsidiaries of Patrick Soon-Shiong's NantWorks LLC...
07:00 , Jun 17, 2013 |  BioCentury  |  Strategy

Grounded in Japan

Amgen Inc. has been developing products in Japan via JVs and partnerships since the early 1980s. Now a new joint venture with Astellas Pharma Inc. will allow the biotech to build its first commercial presence...
07:00 , Jun 3, 2013 |  BC Week In Review  |  Company News

Amgen, Astellas deal

The companies formed a JV, Amgen Astellas BioPharma KK (Tokyo, Japan), to co-develop and co-commercialize five Amgen compounds in Japan. The JV will be responsible for the development and commercialization of the compounds in Japan....
00:13 , May 30, 2013 |  BC Extra  |  Company News

Amgen, Astellas form Japanese JV for Amgen compounds

Amgen Inc. (NASDAQ:AMGN) and Astellas Pharma Inc. (Tokyo:4503) formed a JV, Amgen Astellas BioPharma KK, to co-develop and co-commercialize five Amgen compounds in Japan. The JV will be responsible for the development and commercialization of...